Development of Androgen Independent Prostate Cancer

雄激素非依赖性前列腺癌的发展

• 批准号: 6682247
• 负责人: Susan Kasper
• 金额: $ 31.95万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-07-15 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6682247
• 关键词: androgen receptor; androgens; biological signal transduction; biomarker; cell growth regulation; clinical research; epithelium; hormone sensitivity /resistance; human subject; male; pathologic process; prostate neoplasms; tissue /cell culture; transfection

DESCRIPTION (provided by applicant): The androgen receptor (AR) and the factors that transactivate the AR appear to have the greatest impact on the development and progression of prostate cancer. The removal of androgen by combined androgen blockade does not necessarily mean that the AR signaling pathway is silent and therefore not involved in the progression to androgen-independent disease. We have developed a primary, human prostate epithelial cell transfection assay that can measure the biological activity of the androgen receptor (AR) directly in these cells during the progression from androgen-dependent to androgen-independent growth. The HYPOTHESIS of this study is that the development of androgen-independent prostate cancer is modulated either through AR/co-regulator interactions or through the interactions of other factors which can bind directly to the same AR DNA binding site. The SPECIFIC AIMS of this study are: I. Characterizing the biological activity of the AR in primary HPE cells which represent the progression to androgen-independence. II. Isolating co-regulators from primary HPE cells that bind to AR or to ARBS-2 directly. III. Defining the cooperative interaction of the identified co-regulators with AR or ARBS-2. Our long term goals are to elucidate the mechanisms that govern the switch to androgen-independent human prostate cancer. The molecular mechanisms by which transactivation of the AR facilitates the development of androgen-independence prostate cancer could translate into valuable tools in the clinic as markers for prognosis, provide an assay for predicting hormonal responsiveness to androgen deprivation, and provide potential targets for novel therapies.

描述（由申请人提供）：雄激素受体（AR）和反式激活AR的因子似乎对前列腺癌的发生和进展具有最大的影响。通过联合雄激素阻断去除雄激素并不一定意味着AR信号通路沉默，因此不参与雄激素非依赖性疾病的进展。我们已经开发了一种主要的，人前列腺上皮细胞转染试验，可以直接测量这些细胞中的雄激素受体（AR）的生物活性，从雄激素依赖性的雄激素非依赖性生长的过程中。本研究的假设是，雄激素非依赖性前列腺癌的发展是通过AR/辅助调节因子相互作用或通过其他因子的相互作用来调节的，这些因子可以直接结合到相同的AR DNA结合位点。本研究的具体目标是： I.表征原代HPE细胞中AR的生物活性，其代表雄激素非依赖性的进展。 二.从直接结合AR或ARBS-2的原代HPE细胞中分离共调节因子。 三.定义所识别的协同调节因子与AR或ARBS-2的协同相互作用。 我们的长期目标是阐明控制雄激素非依赖性人类前列腺癌转变的机制。AR的反式激活促进雄激素非依赖性前列腺癌发展的分子机制可以转化为临床上有价值的工具，作为预后的标志物，提供用于预测雄激素剥夺的激素反应性的测定，并提供新疗法的潜在靶点。